Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab

This publication has 22 references indexed in Scilit:

• Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H
  Journal of Clinical Virology, 2006
• A long-term follow-up study on hepatitis B surface antigen–positive patients undergoing allogeneic hematopoietic stem cell transplantation
  Blood, 2005
• Entecavir
  Nature Reviews Drug Discovery, 2005
• Alemtuzumab Induction and Prednisone‐Free Maintenance Immunotherapy in Kidney Transplantation: Comparison with Basiliximab Induction—Long‐Term Results
  American Journal of Transplantation, 2005
• Hepatitis B virus reactivation and alemtuzumab therapy
  European Journal of Haematology, 2005
• Hepatitis B Virus Infection — Natural History and Clinical Consequences
  New England Journal of Medicine, 2004
• Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase
  Gastroenterology, 2003
• Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation
  Hepatology, 2002
• REVERSE SEROCONVERSION OF HEPATITIS B AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION
  Transplantation, 1998
• Is vaccination of donor adequate for clearance of hepatitis B virus after bone-marrow transplantation?
  The Lancet, 1997